Foghorn Therapeutics (FHTX) Cash from Investing Activities (2019 - 2026)

Foghorn Therapeutics' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at -$17.7 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 160.27% year-over-year to -$17.7 million in Q1 2026; TTM through Mar 2026 was $64.9 million, a 335.23% increase from a year earlier, with the FY2025 full-year figure at $112.0 million, up 474.67% from the prior year.
• Cash from Investing Activities retreated to -$17.7 million in Q1 2026 per FHTX's latest filing, from $13.2 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $46.1 million in Q3 2022 and bottomed at -$159.4 million in Q1 2022.
• The 5-year median for Cash from Investing Activities is $27.1 million (2024), against an average of -$2.1 million.
• Across the five-year window, Cash from Investing Activities plunged 4788.35% in 2022 and surged 674.54% in 2023, its largest moves.
• Year by year, Cash from Investing Activities stood at -$6.5 million in 2022, then jumped by 674.54% to $37.4 million in 2023, then plunged by 40.37% to $22.3 million in 2024, then sank by 40.64% to $13.2 million in 2025, then plunged by 233.91% to -$17.7 million in 2026.
• Per Business Quant, the three latest FHTX Cash from Investing Activities figures stand at -$17.7 million (Q1 2026), $13.2 million (Q4 2025), and $35.6 million (Q3 2025).